KUR-023 is delivered from a double barrelled syringe with a mixing spray tip.

The product candidate is delivered as a spray which then arrives on the dura as a liquid, conforms to the surface, and quickly polymerises.

Kuros Biosurgery is planning to enroll around 40 patients in the trial.

The primary endpoint of the trial refers to the prevention of intraoperative leakage with secondary endpoints related to safety and further efficacy assessment.

Kuros Biosurgery CEO Didier Cowling said their dural sealant candidate, KUR-023, is the most advanced product candidate that is based on their proprietary synthetic technology platform.